Login
From:
Drug Discovery and Development
(Uncensored)
subscribe
NKTR jumps 287% after phase 2b win, Lilly lawsuit complicate path
https://www.drugdiscoverytrends.com/nektars-phase-2b-win-triggers-surge-but-legal-tussle-with-lilly-complicates-path-forward/
links
backlinks
Tagged with:
clinical trials
immunology
dermatology
biologics
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.
Roast topics
Find topics
Find it!
